Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary Eli Lilly is acquiring AtaiBeckley, a developer of psychedelic-derived medicines. The deal is valued at roughly $2.8 billion upfront. Additional milestone payments could push the total value toward $3.8
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Summary Ipsen announced the acquisition of Swiss biotech Memo Therapeutics on July 1, 2026. The deal is valued at up to $800 million, with €200 million upfront and more than
Summary AbbVie announced Monday that it will acquire Apogee Therapeutics for $10.9 billion, or $135.11 per share — a 49% premium to Apogee’s closing price. The deal’s centerpiece is zumilokibart,
Overview Between February and June 2026, twelve drugs previously rated by MARA received new regulatory approvals — from the FDA or EMA — triggering a formal surveillance reassessment of each
Overview MARA Rating completed 17 new Reimbursement Risk Assessments in June 2026. The assets span nine therapeutic areas: oncology, obesity, neurology, rare disease, pulmonology, cardiology, immunology, hepatology, and infectious disease.
Summary A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and Bristol Myers Squibb’s Opdivo Qvantig — subcutaneous versions of established
MARA Rating — Back-test series, June 2026 We built MARA to answer one question before the decision arrives: given this evidence profile, how have HTA bodies historically responded to assets
Deal Summary On June 9, 2026, GSK announced the acquisition of Nuvalent for $11 billion — paying $124 per share, a 40% premium over the prior trading price. The deal
We recently rated a one-time gene therapy for Duchenne muscular dystrophy in young boys. The Phase 3 trial was well designed. We looked at the primary endpoint. It was not